More than 30 million people around the world are thought to have Alzheimer"s, with most aged over 65.For around 500,000 people affected in the UK, those eligible for aducanumab will be mostly in their 60s or 70s and at an early stage of the disease.







อ่านต่อเพิ่มเติม> โรงเรียนวัดโบราณาราม
สาระน่ารู้> ความรัก